Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters.
暂无分享,去创建一个
[1] M. Waring. Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.
[2] John P. Overington,et al. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. , 2010, Drug discovery today.
[3] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[4] Brett A Tounge,et al. Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.
[5] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[6] Arun K Mandagere,et al. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. , 2002, Journal of medicinal chemistry.
[7] Peter Ertl,et al. The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.
[8] Samuel H. Yalkowsky,et al. Prediction of Drug Solubility by the General Solubility Equation (GSE) , 2001, J. Chem. Inf. Comput. Sci..
[9] Marta Bellini,et al. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. , 2008, Journal of medicinal chemistry.
[10] Christopher W. Murray,et al. Assessing the lipophilicity of fragments and early hits , 2011, J. Comput. Aided Mol. Des..
[11] Y. Lazebnik. Can a biologist fix a radio? — or, what i learned while studying apoptosis , 2004, Biochemistry (Moscow).
[12] Christopher K. Hsee,et al. When Is More Better? , 2005 .
[13] S. Bembenek,et al. Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.
[14] Marcel L Verdonk,et al. Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.
[15] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[16] P. Andrews,et al. Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.
[17] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[18] D. E. Clark,et al. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.
[19] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[20] Chris de Graaf,et al. Ligand efficiency as a guide in fragment hit selection and optimization. , 2010, Drug discovery today. Technologies.
[21] J. Willem M. Nissink,et al. Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..
[22] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[23] Alexander Hillisch,et al. In Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits , 2006, ChemMedChem.
[24] J J Baldwin,et al. Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.
[25] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[26] Darren V S Green,et al. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.
[27] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[28] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] Tudor I. Oprea. Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..
[30] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[31] Christopher K. Hsee. Less is Better: When Low-Value Options are Valued More Highly than High-Value Options , 1998 .
[32] Tudor I. Oprea,et al. Chemography: the Art of Navigating in Chemical Space , 2000 .
[33] Kazuki Ohno,et al. Two 'Golden Ratio' indices in fragment-based drug discovery. , 2009, Drug discovery today.
[34] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[35] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[36] Daniel J. Warner,et al. Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.
[37] P. N. Craig,et al. Interdependence between physical parameters and selection of substituent groups for correlation studies. , 1971, Journal of medicinal chemistry.
[38] Daniel M. Lowe,et al. ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. , 2009, Bioorganic & medicinal chemistry.
[39] Brett A Tounge,et al. The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.
[40] A. Gill,et al. Kinetic efficiency: the missing metric for enhancing compound quality? , 2011, Drug discovery today.
[41] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[42] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[43] Emanuele Perola,et al. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.
[44] E. Shafir,et al. On the pursuit and misuse of useless information. , 1998, Journal of personality and social psychology.
[45] György G Ferenczy,et al. How are fragments optimized? A retrospective analysis of 145 fragment optimizations. , 2013, Journal of medicinal chemistry.
[46] Cele Abad-Zapatero,et al. Time‐Trajectories in Efficiency Maps as Effective Guides for Drug Discovery Efforts , 2011, Molecular informatics.
[47] S. Planey,et al. The influence of lipophilicity in drug discovery and design , 2012, Expert opinion on drug discovery.
[48] Anne Mai Wassermann,et al. SARANEA: A Freely Available Program To Mine Structure-Activity and Structure-Selectivity Relationship Information in Compound Data Sets , 2010, J. Chem. Inf. Model..
[49] M. Edwards,et al. Using the Golden Triangle to optimize clearance and oral absorption. , 2009, Bioorganic & medicinal chemistry letters.
[50] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .
[51] Paul D Leeson,et al. Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.
[52] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[53] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[54] Stephen D Pickett,et al. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. , 2011, Drug discovery today.
[55] Akos Tarcsay,et al. Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.
[56] Paul D. Leeson,et al. Impact of ion class and time on oral drug molecular properties , 2011 .
[57] D C Spellmeyer,et al. Measuring diversity: experimental design of combinatorial libraries for drug discovery. , 1995, Journal of medicinal chemistry.
[58] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.